PURPOSE: The goal of this study was to examine the effect of tobacco use on disease recurrence (local/regional recurrence, distant metastasis, or second primary) among patients with human papillomavirus (HPV)-positive squamous cell carcinoma of the oropharynx (SCCOP) following a complete response to chemoradiation therapy. EXPERIMENTAL DESIGN: Between 1999 and 2007, 124 patients with advanced SCCOP (86% with stage IV) and adequate tumor tissue for HPV analysis who were enrolled in one of two consecutive University of Michigan treatment protocols were prospectively included in this study. Patients were categorized as never-, former, or current tobacco users. The primary end points were risk of disease recurrence and time to recurrence; secondary end points were disease-specific survival and overall survival. RESULTS: One hundred and two patients (82.3%) had HPV-positive tumors. Over two thirds (68%) of patients with HPV-positive tumors were tobacco users. Among HPV-positive patients, current tobacco users were at significantly higher risk of disease recurrence than never-tobacco users (hazard ratio, 5.2; confidence interval, 1.1-24.4; P = 0.038). Thirty-five percent of HPV-positive ever tobacco users recurred compared with only 6% of HPV-positive never users and 50% of HPV-negative patients. All HPV-negative patients were tobacco users and had significantly shorter times to recurrence (P = 0.002), and had reduced disease-specific survival (P = 0.004) and overall survival (P < 0.001) compared with HPV-positive patients. Compared with HPV-positive never-tobacco users, those with a tobacco history showed a trend for reduced disease-specific survival (P = 0.064) but not overall survival (P = 0.221). CONCLUSIONS: Current tobacco users with advanced, HPV-positive SCCOP are at higher risk of disease recurrence compared with never-tobacco users.
PURPOSE: The goal of this study was to examine the effect of tobacco use on disease recurrence (local/regional recurrence, distant metastasis, or second primary) among patients with human papillomavirus (HPV)-positive squamous cell carcinoma of the oropharynx (SCCOP) following a complete response to chemoradiation therapy. EXPERIMENTAL DESIGN: Between 1999 and 2007, 124 patients with advanced SCCOP (86% with stage IV) and adequate tumor tissue for HPV analysis who were enrolled in one of two consecutive University of Michigan treatment protocols were prospectively included in this study. Patients were categorized as never-, former, or current tobacco users. The primary end points were risk of disease recurrence and time to recurrence; secondary end points were disease-specific survival and overall survival. RESULTS: One hundred and two patients (82.3%) had HPV-positive tumors. Over two thirds (68%) of patients with HPV-positive tumors were tobacco users. Among HPV-positive patients, current tobacco users were at significantly higher risk of disease recurrence than never-tobacco users (hazard ratio, 5.2; confidence interval, 1.1-24.4; P = 0.038). Thirty-five percent of HPV-positive ever tobacco users recurred compared with only 6% of HPV-positive never users and 50% of HPV-negative patients. All HPV-negative patients were tobacco users and had significantly shorter times to recurrence (P = 0.002), and had reduced disease-specific survival (P = 0.004) and overall survival (P < 0.001) compared with HPV-positive patients. Compared with HPV-positive never-tobacco users, those with a tobacco history showed a trend for reduced disease-specific survival (P = 0.064) but not overall survival (P = 0.221). CONCLUSIONS: Current tobacco users with advanced, HPV-positive SCCOP are at higher risk of disease recurrence compared with never-tobacco users.
Authors: R Klaes; T Friedrich; D Spitkovsky; R Ridder; W Rudy; U Petry; G Dallenbach-Hellweg; D Schmidt; M von Knebel Doeberitz Journal: Int J Cancer Date: 2001-04-15 Impact factor: 7.396
Authors: M L Gillison; W M Koch; R B Capone; M Spafford; W H Westra; L Wu; M L Zahurak; R W Daniel; M Viglione; D E Symer; K V Shah; D Sidransky Journal: J Natl Cancer Inst Date: 2000-05-03 Impact factor: 13.506
Authors: Carole Fakhry; William H Westra; Sigui Li; Anthony Cmelak; John A Ridge; Harlan Pinto; Arlene Forastiere; Maura L Gillison Journal: J Natl Cancer Inst Date: 2008-02-12 Impact factor: 13.506
Authors: Bhavna Kumar; Kitrina G Cordell; Julia S Lee; Francis P Worden; Mark E Prince; Huong H Tran; Gregory T Wolf; Susan G Urba; Douglas B Chepeha; Theodoros N Teknos; Avraham Eisbruch; Christina I Tsien; Jeremy M G Taylor; Nisha J D'Silva; Kun Yang; David M Kurnit; Joshua A Bauer; Carol R Bradford; Thomas E Carey Journal: J Clin Oncol Date: 2008-05-12 Impact factor: 44.544
Authors: Francis P Worden; Bhavna Kumar; Julia S Lee; Gregory T Wolf; Kitrina G Cordell; Jeremy M G Taylor; Susan G Urba; Avraham Eisbruch; Theodoros N Teknos; Douglas B Chepeha; Mark E Prince; Christina I Tsien; Nisha J D'Silva; Kun Yang; David M Kurnit; Heidi L Mason; Tamara H Miller; Nancy E Wallace; Carol R Bradford; Thomas E Carey Journal: J Clin Oncol Date: 2008-05-12 Impact factor: 44.544
Authors: Harriët C Hafkamp; J J Manni; A Haesevoets; A C Voogd; M Schepers; F J Bot; A H N Hopman; F C S Ramaekers; Ernst-Jan M Speel Journal: Int J Cancer Date: 2008-06-15 Impact factor: 7.396
Authors: Elizabeth A Sisk; Scott G Soltys; Shaobo Zhu; Susan G Fisher; Thomas E Carey; Carol R Bradford Journal: Head Neck Date: 2002-09 Impact factor: 3.147
Authors: Alice L Tang; Samantha J Hauff; John H Owen; Martin P Graham; Michael J Czerwinski; Jung Je Park; Heather Walline; Silvana Papagerakis; Jay Stoerker; Jonathan B McHugh; Douglas B Chepeha; Carol R Bradford; Thomas E Carey; Mark E Prince Journal: Head Neck Date: 2011-12-13 Impact factor: 3.147
Authors: Lisa A Peterson; Emily L Bellile; Gregory T Wolf; Shama Virani; Andrew G Shuman; Jeremy M G Taylor; Laura S Rozek Journal: Head Neck Date: 2016-07-19 Impact factor: 3.147
Authors: William Strober; Sachie Shishido; Burton Wood; James S Lewis; Krystle Kuhs; Robert L Ferris; Daniel L Faden Journal: Oral Oncol Date: 2019-11-22 Impact factor: 5.337
Authors: Olcay Cem Bulut; Katja Lindel; Henrik Hauswald; Regine Brandt; Frederick Klauschen; Janina Wolf; Thomas Wolf; Peter K Plinkert; Christian Simon; Wilko Weichert; Albrecht Stenzinger Journal: Eur Arch Otorhinolaryngol Date: 2013-08-29 Impact factor: 2.503
Authors: Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz Journal: Head Neck Date: 2012-01-27 Impact factor: 3.147
Authors: Matthew H Stenmark; Jonathan B McHugh; Matthew Schipper; Heather M Walline; Christine Komarck; Felix Y Feng; Francis P Worden; Gregory T Wolf; Douglas B Chepeha; Mark E Prince; Carol R Bradford; Suresh K Mukherji; Avraham Eisbruch; Thomas E Carey Journal: Int J Radiat Oncol Biol Phys Date: 2014-03-01 Impact factor: 7.038
Authors: Mary Roz Timbang; Michael W Sim; Arnaud F Bewley; D Gregory Farwell; Avinash Mantravadi; Michael G Moore Journal: Hum Vaccin Immunother Date: 2019-05-07 Impact factor: 3.452
Authors: Moonef Alotaibi; Valeria Valova; Toni HÄnsel; Carmen Stromberger; Grzegorz Kofla; Heidi Olze; Iris Piwonski; Andreas Albers; Sebastian Ochsenreither; Annekatrin Coordes Journal: In Vivo Date: 2021 Mar-Apr Impact factor: 2.155
Authors: Jeffrey M Vainshtein; Matthew E Spector; Mohannad Ibrahim; Carol R Bradford; Gregory T Wolf; Matthew H Stenmark; Francis P Worden; Jonathan B McHugh; Mark E Prince; Thomas Carey; Douglas B Chepeha; Avraham Eisbruch Journal: Head Neck Date: 2015-07-15 Impact factor: 3.147